Issue 1/2018
Content (12 Articles)
Value-Based Pricing: L’Enfant Terrible?
Sarah Garner, Andrew Rintoul, Suzanne R. Hill
Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment
Jaclyn Beca, Don Husereau, Kelvin K. W. Chan, Neil Hawkins, Jeffrey S. Hoch
Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review
Alisha Monnette, Yichen Zhang, Hui Shao, Lizheng Shi
Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Hazel Squires, Abdullah Pandor, Praveen Thokala, John W. Stevens, Eva Kaltenthaler, Mark Clowes, Robert Coleman, Lynda Wyld
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
Irina A. Tikhonova, Tracey Jones-Hughes, James Dunham, Fiona C. Warren, Sophie Robinson, Peter Stephens, Martin Hoyle
The Use of Decision–Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal
Emma McManus, Tracey Sach, Nick Levell
Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis
Samuel Herzog, Marian Shanahan, Peter Grimison, Anh Tran, Nicole Wong, Nicholas Lintzeris, John Simes, Martin Stockler, Rachael L. Morton
Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework
Natalie Carvalho, Mark Jit, Sarah Cox, Joanne Yoong, Raymond C. W. Hutubessy
Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
Amir Ansaripour, Carin A. Uyl-de Groot, W. Ken Redekop
Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
Thea van Asselt, Bram Ramaekers, Isaac Corro Ramos, Manuela Joore, Maiwenn Al, Ivonne Lesman-Leegte, Maarten Postma, Pepijn Vemer, Talitha Feenstra
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
Usha G. Mallya, Susan H. Boklage, Andrew Koren, Thomas E. Delea, C. Daniel Mullins